Out of 2,341 studies, 31 articles met inclusion criteria. Cannabigerol (range 5 to 20 mg·kg?1) and cannabidivarin (range 0.2 to 400 mg·kg?1) displayed efficacy in models of Huntington’s disease and epilepsy. Cannabichromene (10–75 mg·kg?1), ?9-tetrahydrocannabinolic acid (20 mg·kg?1), and tetrahydrocannabivarin (range 0.025–2.5 mg·kg?1) showed promise in models of seizure and hypomobility, Huntington’s and Parkinson’s disease. Limited mechanistic data showed cannabigerol, its derivatives VCE.003 and VCE.003.2, and ?9-tetrahydrocannabinolic acid mediated some of their effects through PPAR-?, but no other receptors were probed.